Fanotaprim

小分子

法诺普林

Fanotaprim

F651948-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC 50 s of 1.57 and 308 nM for tg DHFR ( Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis. In Vitro Fanotaprim shows parasiticidal and antiproliferative effects with EC 50 s of 13 and 7300 nM against the type I RH strain of T. gondii and MCF-7 cells, respectively. Fanotaprim shows ability to inhibit the growth of T. gondii strains in vitro with EC 50 s ranging 7.6~ 29.8 nM (GT1, ME49, CTG, RUB and VAND). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Fanotaprim (1-10 mg/kg; p.o.; daily; beginning on day 1 through day 7) shows highly effective in control of acute infection by highly virulent strains of T. gondii in the murine model . Fanotaprim (1mg/kg; i.v; mouse) shows C L , V d , and t 1/2 values of 10.6 mL/min/kg, 1.14 L/kg, and 3.9 hours, respectively . Fanotaprim (0.83 mg/kg; p.o; mouse) shows F, C max , T max , and AUC 0-last of 47.3%, 178 ng/mL, 0.05 hours and 750 ng h/mL, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: CD-1female mice (murine model of acute toxoplasmosis) Dosage: 1-10 mg/kg Administration: p.o.; daily; beginning on day 1 through day 7 Result: Mice were monitored for survival for 30 days within termittent IVIS monitoring. At doses of 10 mg/kg Fanotaprim, q.d. or b.i.d. for 7 days, yielded 100% survival for 30 days. Form:Solid

法诺他普林是一种二氢叶酸还原酶（DHFR）抑制剂，对 tg DHFR（弓形虫 DHFR）和 hDHFR（人类 DHFR）的 IC 50 s 分别为 1.57 和 308 nM。Fanotaprim 具有研究弓形虫病的潜力。

2120282-75-7

C19H22N8O

378.43 g/mol

134812633

COC1=NC=C(C=N1)C2=CC(=CC=C2)N3CCN(CC3)C4=CN=C(N=C4N)N

COC1=NC=C(C=N1)C2=CC(=CC=C2)N3CCN(CC3)C4=CN=C(N=C4N)N

134812633

DMSO : 33.33 mg/mL (88.07 mM; ultrasonic and warming and heat to 60°C)

2

9

4

378.192 Da

378.192 Da

119.000 Ų

28

0

481.000

0

1

1.400